%0 Journal Article %J J Alzheimers Dis %D 2016 %T Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease. %A Bonet-Costa, Vicent %A Herranz-Pérez, Vicente %A Blanco-Gandía, MariCarmen %A Mas-Bargues, Cristina %A Inglés, Marta %A Garcia-Tarraga, Patricia %A Rodriguez-Arias, Marta %A Miñarro, Jose %A Borras, Consuelo %A Garcia-Verdugo, Jose Manuel %A Viña, Jose %K Alzheimer Disease %K Amyloid beta-Peptides %K Animals %K Apolipoproteins E %K Astrocytes %K Avoidance Learning %K Brain %K Cells, Cultured %K Disease Models, Animal %K Female %K Genistein %K Habituation, Psychophysiologic %K Maze Learning %K Mice, Inbred C57BL %K Mice, Transgenic %K Neuroprotective Agents %K Nootropic Agents %K Olfactory Perception %K Plaque, Amyloid %K PPAR gamma %K Recognition (Psychology) %K Tetrahydronaphthalenes %X

Amyloid-β (Aβ) clearance from brain, which is decreased in Alzheimer's disease, is facilitated by apolipoprotein E (ApoE). ApoE is upregulated by activation of the retinoid X receptor moiety of the RXR/PPARγ dimeric receptor. Genistein, a non-toxic, well-tested, and inexpensive drug activates the other moiety of the receptor PPARγ. Treatment of an Alzheimer's disease mouse model with genistein results in a remarkable and rapid improvement in various parameters of cognition, such as hippocampal learning, recognition memory, implicit memory, and odor discrimination. This is associated with a lowering of Aβ levels in brain, in the number and the area of amyloid plaques (confirmed in vivo by positron emission tomography) as well as in microglial reactivity. Finally, incubation of primary astrocytes with genistein results in a PPARγ-mediated increased release of ApoE. Our results strongly suggest that controlled clinical trials should be performed to test the effect of genistein as treatment of human Alzheimer's disease.

%B J Alzheimers Dis %V 51 %P 701-11 %8 2016 %G eng %N 3 %1 http://www.ncbi.nlm.nih.gov/pubmed/26890773?dopt=Abstract %R 10.3233/JAD-151020